Unituxin IV infusion 17.5mg/5mL, manufactured by Ohara Pharmaceutical, contains Dinutuximab (genetical recombination). This monoclonal antibody binds to GD2 on neuroblastoma cells, leading to cell lysis through antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. It is provided as 17.5mg in 5mL per bottle, with YJ code 4291457A1025.
Unituxin IV infusion 17.5mg/5mL
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →